BridgeBio's BBP-812 Canavan Disease Gene Therapy Receives FDA RMAT Designation
11/9 05:18
(RTTNews) - BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy or RMAT designation to BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treat...